Evidence map›Paper›PMID 34845234›Full record

ArticleNPJ Parkinson's disease2021

Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis.

J M Hatcher-Martin, J L McKay, A F Pybus, B Sommerfeld, J C Howell, F C Goldstein, L Wood, W T Hu, S A Factor

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Fluid and Biopsy Based Biomarkers in Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

J M Hatcher-Martin *Jean & Paul Amos PD & Movement Disorders Program, Department of Neurology, Emory University, Atlanta, GA, USA.
J L McKay *Jean & Paul Amos PD & Movement Disorders Program, Department of Neurology, Emory University, Atlanta, GA, USA.
A F PybusDepartment of Mechanical Engineering, Georgia Tech, Atlanta, GA, USA.
B SommerfeldJean & Paul Amos PD & Movement Disorders Program, Department of Neurology, Emory University, Atlanta, GA, USA.
J C HowellNeurology Consultants of Dallas, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-9527-4239
F C GoldsteinNeuropsychology Program, Department of Neurology, Emory University, Atlanta, GA, USA.
L WoodDepartment of Mechanical Engineering, Georgia Tech, Atlanta, GA, USA.
W T HuAlzheimer's Disease Research Center, Emory University and Cognitive Neurology Division, Rutgers-Robert Wood Johnson Medical School and Institute for Health, Health Care Policy, and Aging Research, Atlanta, GA, USA.
S A Factor *Jean & Paul Amos PD & Movement Disorders Program, Department of Neurology, Emory University, Atlanta, GA, USA. sfactor@emory.edu.ORCID http://orcid.org/0000-0002-0449-973X
Emory University · USGeorgia Institute of Technology · USTexas Neurology · US

Funding

Neural mechanisms of balance deficits, falls, and freezing of gait in Parkinson's diseaseK25HD086276 · NICHD · EMORY UNIVERSITY · PI MCKAY, JOHNATHAN LUCAS · 2016 to 2019
$509k
NICHD NIH HHS K25 HD086276
6 · The paper itself

Abstract

We explore the association between three Alzheimer's disease-related and ten inflammation-related CSF markers and freezing of gait (FOG) in patients with Parkinson's disease (PD). The study population includes PD patients with FOG (PD-FOG, N = 12), without FOG (PD-NoFOG, N = 19), and healthy controls (HC, N = 12). Age and PD duration are not significantly different between groups. After adjusting for covariates and multiple comparisons, the anti-inflammatory marker, fractalkine, is significantly decreased in the PD groups compared to HC (P = 0.002), and further decreased in PD-FOG compared to PD-NoFOG (P = 0.007). The Alzheimer's disease-related protein, Aβ42, is increased in PD-FOG compared to PD-NoFOG and HC (P = 0.001). Group differences obtained in individual biomarker analyses are confirmed with multivariate discriminant partial least squares regression (P < 0.001). High levels of Aβ42 in PD-FOG patients supports an increase over time from early to advanced state. Low levels of fractalkine might suggest anti-inflammatory effect. These findings warrant replication.

Identifiers

PMID34845234
PMCPMC8629994
OpenAlexW3216553618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.